Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulcrum Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulcrum Therapeutics's regulatory disclosures and financial reporting.
Fulcrum Therapeutics director Rachel K. King received a grant of stock options covering 32,000 shares of common stock. These options give her the right to buy shares at an exercise price of $3.66 per share, aligning part of her compensation with the company’s future performance.
The option grant is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, as long as she continues in service. After this grant, she holds options for 32,000 underlying shares that expire on June 29, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Fulcrum Therapeutics, Inc. director James A. Geraghty received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $3.66 per share and expire on June 29, 2036. According to the grant terms, all 32,000 options are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, subject to his continued service.
Fulcrum Therapeutics director Colin Hill received a stock option grant covering 32,000 shares of Common Stock. The option has an exercise price of $3.66 per share and was granted as a compensation award, not as an open-market purchase or sale.
The option was granted on June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, subject to continued service. Following this grant, Hill holds options for 32,000 shares directly, with an expiration date of June 29, 2036.
Fulcrum Therapeutics, Inc. director Alan Ezekowitz received a stock option grant covering 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036.
According to the terms, the option is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual stockholder meeting after the grant date, as long as service continues. Following this grant, his reported derivative holdings for this option total 32,000 shares.
Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock. He sold 18,000 shares of Fulcrum Therapeutics, Inc. at a weighted average price of $3.6452 per share, executed as multiple trades within a disclosed price range.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Following this sale, Ezekowitz directly holds 10,927 shares of Fulcrum Therapeutics common stock.
Fulcrum Therapeutics reports large passive holdings by EcoR1 and affiliated parties. EcoR1 Capital, LLC and Oleg Nodelman each report beneficial ownership of 6,000,000 shares (listed as 9.0% of common stock), and EcoR1 Capital Fund Qualified, L.P. reports 5,614,199 shares (8.4%), with percentages calculated using 66,633,321 shares outstanding as of April 20, 2026. The filing states shared voting and dispositive power for the reported holdings and includes a joint-filing agreement; the reporting persons disclaim group status and certain beneficial ownership beyond pecuniary interests.
EcoR1 Capital and related persons report beneficial ownership of Fulcrum Therapeutics common stock. The filing states EcoR1 Capital, LLC and Oleg Nodelman each have shared voting and dispositive power over 6,000,000 shares (reported as 9.0% of the class). It also shows EcoR1 Capital Fund Qualified, L.P. holds 5,614,199 shares (reported as 8.4%). The percentages are calculated using 66,633,321 shares outstanding as of April 20, 2026, per the issuer's Form 10-Q for the quarter ended March 31, 2026. The filing includes a joint-filing agreement and statements disclaiming group membership beyond the reporting relationship.
Fulcrum Therapeutics, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 24, 2026. Stockholders voted on the election of three director nominees and two additional proposals.
For the board seats, Sonja Banks received 43,187,717 votes for and 10,601,385 votes withheld, while Alan Ezekowitz received 52,317,282 votes for and 1,471,820 votes withheld. Colin Hill received 52,363,595 votes for and 1,425,507 votes withheld. Each director vote included 5,062,117 broker non-votes.
A separate proposal received 50,735,617 votes for, 3,026,397 votes against, 27,088 abstentions and 5,062,117 broker non-votes. Another proposal received 58,793,645 votes for, 36,178 votes against and 21,396 abstentions with no broker non-votes reported.
Fulcrum Therapeutics approved special retention and change-in-control protections for its remaining leadership after a major restructuring tied to ending development of pociredir for sickle cell disease. The compensation committee granted cash retention bonuses to nine remaining full-time employees, including top executives.
President and CEO Alex C. Sapir will receive $370,040, and Chief Legal Officer Curtis Oltmans and Chief Financial Officer Alan Musso will receive $195,480 and $195,200, respectively, payable in cash if there is a qualifying change in control or a termination without cause, subject to completion of transitional duties. Their employment agreements were amended to align retention payments with incremental change-in-control benefits.
The company also extended change-in-control benefits to remaining employees at the Vice President level and above on similar terms. Separately, Fulcrum disclosed that Vice President, Finance and principal accounting officer Greg Tourangeau will depart on a mutually agreed future date, and stated his departure is not due to any disagreement regarding financial reporting or controls.